A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose
ID Number 15-2244Principal Investigator(s)
John O Mascarenhas
Department(s) or Division(s)
Hematology and Medical Oncology
You have been asked to take part in this study because you have been diagnosed with myelofibrosis and your cancer has returned after treatment with a Janus Kinase (JAK) Inhibitor. Myelofibrosis is a type of cancer that affects the production of blood cells.
The purpose of this study is to find the dose of imetelstat that best treats myelofibrosis. The effects of imetelstat on myelofibrosis as well as any side effects will be explored.
Recruiting Patients: Yes